|
1
|
Ricard D, Idbaih A, Ducray F, Lahutte M,
Hoang-Xuan K and Delattre JY: Primary brain tumours in adults.
Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee JH, Jung TY, Jung S, Kim IY, Jang WY,
Moon KS and Jeong EH: Performance status during and after
radiotherapy plus concomitant and adjuvant temozolomide in elderly
patients with glioblastoma multiforme. J Clin Neurosci. 20:503–508.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Calin GA, Liu CG, Sevignani C, Ferracin M,
Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al:
MicroRNA profiling reveals distinct signatures in B cell chronic
lymphocytic leukemias. Proc Natl Acad Sci USA. 101:11755–11760.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Weber F, Teresi RE, Broelsch CE, Frilling
A and Eng C: A limited set of human MicroRNA is deregulated in
follicular thyroid carcinoma. J Clin Endocrinol Metab.
91:3584–3591. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jun GJ, Zhong GG and Ming ZS: miR-218
inhibits the proliferation of glioma U87 cells through the
inactivation of the CDK6/cyclin D1/p21Cip1/Waf1 pathway. Oncol
Lett. 9:2743–2749. 2015.PubMed/NCBI
|
|
7
|
Jiang L, Wang C, Lei F, Zhang L, Zhang X,
Liu A, Wu G, Zhu J and Song L: miR-93 promotes cell proliferation
in gliomas through activation of PI3K/Akt signaling pathway.
Oncotarget. 6:8286–8299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hou SX, Ding BJ, Li HZ, Wang L, Xia F, Du
F, Liu LJ, Liu YH, Liu XD, Jia JF, et al: Identification of
microRNA-205 as a potential prognostic indicator for human glioma.
J Clin Neurosci. 20:933–937. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sand M, Skrygan M, Sand D, Georgas D,
Gambichler T, Hahn SA, Altmeyer P and Bechara FG: Comparative
microarray analysis of microRNA expression profiles in primary
cutaneous malignant melanoma, cutaneous malignant melanoma
metastases, and benign melanocytic nevi. Cell Tissue Res.
351:85–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun B, Li L, Ma W, Wang S and Huang C:
MiR-130b inhibits proliferation and induces apoptosis of gastric
cancer cells via CYLD. Tumour Biol. 37:7981–7987. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Egawa H, Jingushi K, Hirono T, Ueda Y,
Kitae K, Nakata W, Fujita K, Uemura M, Nonomura N and Tsujikawa K:
The miR-130 family promotes cell migration and invasion in bladder
cancer through FAK and Akt phosphorylation by regulating PTEN. Sci
Rep. 6:205742016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Colangelo T, Fucci A, Votino C, Sabatino
L, Pancione M, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente
D, et al: MicroRNA-130b promotes tumor development and is
associated with poor prognosis in colorectal cancer. Neoplasia.
15:1086–1099. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu T, Cao R, Li S, Fu M, Ren L, Chen W,
Zhu H, Zhan Q and Shi R: MiR-130b plays an oncogenic role by
repressing PTEN expression in esophageal squamous cell carcinoma
cells. BMC Cancer. 15:292015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gu JJ, Zhang JH, Chen HJ and Wang SS:
MicroRNA-130b promotes cell proliferation and invasion by
inhibiting peroxisome proliferator-activated receptor-γ in human
glioma cells. Int J Mol Med. 37:1587–1593. 2016.PubMed/NCBI
|
|
15
|
Dettmer MS, Perren A, Moch H, Komminoth P,
Nikiforov YE and Nikiforova MN: MicroRNA profile of poorly
differentiated thyroid carcinomas: New diagnostic and prognostic
insights. J Mol Endocrinol. 52:181–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li BL, Lu C, Lu W, Yang TT, Qu J, Hong X
and Wan XP: miR-130b is an EMT-related microRNA that targets DICER1
for aggression in endometrial cancer. Med Oncol. 30:4842013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leone V, Langella C, D'Angelo D, Mussnich
P, Wierinckx A, Terracciano L, Raverot G, Lachuer J, Rotondi S,
Jaffrain-Rea ML, et al: Mir-23b and miR-130b expression is
downregulated in pituitary adenomas. Mol Cell Endocrinol. 390:1–7.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao G, Zhang JG, Shi Y, Qin Q, Liu Y,
Wang B, Tian K, Deng SC, Li X, Zhu S, et al: MiR-130b is a
prognostic marker and inhibits cell proliferation and invasion in
pancreatic cancer through targeting STAT3. PLoS One. 8:e738032013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mei Q, Li F, Quan H, Liu Y and Xu H:
Busulfan inhibits growth of human osteosarcoma through miR-200
family microRNAs in vitro and in vivo. Cancer Sci. 105:755–762.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim
MM, Srikantan S, Martindale JL, Hutchison ER, Kim HH, Marasa BS, et
al: miR-130 suppresses adipogenesis by inhibiting peroxisome
proliferator-activated receptor gamma expression. Mol Cell Biol.
31:626–638. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gong X, Zhang K, Wang Y, Wang J, Cui Y, Li
S and Luo Y: MicroRNA-130b targets Fmr1 and regulates embryonic
neural progenitor cell proliferation and differentiation. Biochem
Biophys Res Commun. 439:493–500. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM,
Li Y, Nelson RA, Mu B, Onami SH, et al: Identification of a
4-microRNA signature for clear cell renal cell carcinoma metastasis
and prognosis. PLoS One. 7:e356612012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Trompouki E, Hatzivassiliou E, Tsichritzis
T, Farmer H, Ashworth A and Mosialos G: CYLD is a deubiquitinating
enzyme that negatively regulates NF-kappaB activation by TNFR
family members. Nature. 424:793–796. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun SC: CYLD: A tumor suppressor
deubiquitinase regulating NF-kappaB activation and diverse
biological processes. Cell Death Differ. 17:25–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xue L, Igaki T, Kuranaga E, Kanda H, Miura
M and Xu T: Tumor suppressor CYLD regulates JNK-induced cell death
in Drosophila. Dev Cell. 13:446–454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tauriello DV, Haegebarth A, Kuper I,
Edelmann MJ, Henraat M, Canninga-van Dijk MR, Kessler BM, Clevers H
and Maurice MM: Loss of the tumor suppressor CYLD enhances
Wnt/beta-catenin signaling through K63-linked ubiquitination of
Dvl. Mol Cell. 37:607–619. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Massoumi R, Kuphal S, Hellerbrand C, Haas
B, Wild P, Spruss T, Pfeifer A, Fässler R and Bosserhoff AK:
Down-regulation of CYLD expression by Snail promotes tumor
progression in malignant melanoma. J Exp Med. 206:221–232. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Espinosa L, Cathelin S, D'Altri T,
Trimarchi T, Statnikov A, Guiu J, Rodilla V, Inglés-Esteve J,
Nomdedeu J, Bellosillo B, et al: The Notch/Hes1 pathway sustains
NF-κB activation through CYLD repression in T cell leukemia. Cancer
Cell. 18:268–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hellerbrand C, Bumes E, Bataille F,
Dietmaier W, Massoumi R and Bosserhoff AK: Reduced expression of
CYLD in human colon and hepatocellular carcinomas. Carcinogenesis.
28:21–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C,
Wu J, Hu B, Cheng SY, Li M, et al: TGF-β induces miR-182 to sustain
NF-κB activation in glioma subsets. J Clin Invest. 122:3563–3578.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liang HL, Hu AP, Li SL, Xie JP, Ma QZ and
Liu JY: MiR-454 prompts cell proliferation of human colorectal
cancer cells by repressing CYLD expression. Asian Pac J Cancer
Prev. 16:2397–2402. 2015. View Article : Google Scholar : PubMed/NCBI
|
